ONCAlert | 2018 SGO Annual Meeting on Women’s Cancer
Videos  >  

The Approval of Ibrutinib for MCL

Anas Younes, MD
Published Online:2:10 PM, Mon May 19, 2014
Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the implications of ibrutinib’s approval for patients with mantle cell lymphoma (MCL).

Clinical Pearls:
  • Prior to ibrutinib’s approval, patients with MCL had no additional options once they failed their first induction therapy.
  • Most patients with MCL are over age 65 and are therefore not candidates for transplant. These patients were previously treated with some sort of induction chemotherapy like R-CHOP followed by rituximab maintenance therapy.
  • Before ibrutinib, younger patients with MCL previously had no valid option following relapse from transplant and induction therapy, which are incorporated into one package.
  • Ibrutinib is beneficial to patients with MCL as it is an oral drug that has demonstrated a durable response rate with minimal side effects.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.